Show results for
Refine by
Syringe With Fixed Safety Needle 7 Dose Syringe Articles & Analysis
9 news found
Australian biotechnology company, Vaxxas Pty Ltd (Vaxxas), in collaboration with the University of Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, has completed a study assessing the usability and acceptability of its novel High-Density Microarray Patch (HD-MAP) to administer vaccines. The HD-MAP is Vaxxas’ proprietary vaccine patch technology, representing a ...
Gerresheimer AG is expanding its portfolio of highly-innovative platform technologies for drug delivery. Gerresheimer, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, today announced an investment into US-based Portal Instruments, a developer of a next-generation needle-free drug delivery technology. Together, the partners aim ...
There are self-driving cars, 5G smartphones, and now planes that travel from New York to London in 3.5 hours. The world we live in and the technology we use are rapidly evolving. But, when it comes to drug delivery methods, the 160-year old technology behind the needle and syringe has yet to catch wind of any radical transformation. With cutting-edge technology from MIT, Portal Instruments aims ...
Numedico Technologies Pty Ltd (Numedico) and Omikron Group Ltd (OGL) are pleased to announce the completion and settlement of the acquisition of the global ClickZip assets and Omikron business. Signed in May 2020, the acquistion brings the assets and international business of the ClickZip® Needle Retractable Safety Syringe into Numedico’s expanding portfolio of safe medical devices and ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella. ...
Innovative needle-free injectable unit solid-dose presentation of recombinant H7N9 pandemic flu vaccine, created using Enesi’s ImplaVax technology, generated immune responses comparable with liquid vaccine and demonstrated excellent thermal stability at temperatures up to 40°C for six months. Enesi Pharma (“Enesi”), an innovative biotechnology company developing ...
Enesi Pharma recently hosted a crew from Asahi TV, one of Japan’s leading TV channels, at its Oxford, UK facility to talk about the potential of its ImplaVax® solid dose needle-free vaccination technology. The conversation coincided with the approval of the Pfizer/BioNTech COVID-19 vaccine Comirnaty® in Japan and potential dose-wasting issues linked to the type of syringe used in ...
Under $6.745 Million Grant from the Bill & Melinda Gates Foundation ATLANTA, Sept. 1, 2020 /PRNewswire/ — Micron Biomedical, Inc. (Micron) recently received a second tranche of funding ($2.6M) to continue clinical development of its microneedle-based technology for measles and rubella vaccination from the Bill & Melinda Gates Foundation. This work leverages Micron’s ...
Sharps Compliance Corp. (NASDAQ: SMED), a leading full-service provider of cost-effective management solutions for medical waste and unused dispensed medications generated outside the hospital and large healthcare facility setting, is helping healthcare professionals including doctors, dentists, vets, clinics, assisted living and skilled nursing facilities save time, money and the environment ...